Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors
Public ClinicalTrials.gov record NCT05309187. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination With Pembrolizumab in Subjects With Advanced, Relapsed, or Refractory Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess safety and tolerability of increasing doses of IO-202 either as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors, and select the recommended Phase 2 dose (RP2D).
Study identification
- NCT ID
- NCT05309187
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Interventions
- IO-202 Biological
- IO-202 + pembrolizumab combination therapy Biological
- RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 11, 2022 (Actual)
- Primary completion
- Mar 29, 2024 (Actual)
- Completion
- May 31, 2024 (Actual)
- Last update posted
- Jun 4, 2024
2022 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC-Norris Comprehensive Cancer Center (119) | Los Angeles | California | 90033 | — |
| University of Florida (125) | Gainesville | Florida | 32610-0278 | — |
| Northwestern University - Feinberg School of Medicine (133) | Chicago | Illinois | 60611 | — |
| Indiana University (123) | Indianapolis | Indiana | 46202 | — |
| Tisch Mount Sinai (124) | New York | New York | 10029 | — |
| Carolina BioOncology (102) | Huntsville | North Carolina | 28078 | — |
| Sarah Cannon Research Institute/Tennessee Oncology (122) | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research (108) | Dallas | Texas | 75251 | — |
| MD Anderson Cancer Center (101) | Houston | Texas | 77030 | — |
| NEXT Oncology Virginia (121) | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05309187, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2024 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05309187 live on ClinicalTrials.gov.